TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: offspring mental outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety of PRP gel application
Endpoint domain: Adverse events/effects
Primary endpoint: Subjective Ease of Lens Removal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in shame
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Healing of bone cyst defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Symptomatic Virologically-Confirmed Dengue Cases
Endpoint domain: Adverse events/effects
Primary endpoint: Change in severity of onychomycosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of albaconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of aggregation of platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amount of Alcohol Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in RV function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Passive Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spasticity Measurement with AShworth and Tardieu Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Muscle Strength and Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline occupational burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline work engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Total Sum Score (WOMAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Negative GBS screening in vaginal samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Growth Rate in Lower-leg Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Minimal Hepatic Encephalopathy (MHE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to neurocognitive decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Facial micro expression detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biological activity of CP-4126
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes From Baseline in Home Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Factors influencing choice of breast reconstruction
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Virology Cure Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with Type 6 or Type 7 stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Participants Who Achieved >5% Weight Loss at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient health status improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunogenicity indexes of neutralizing-antibody seroconversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUEC0-inf for anti-FXa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUEC0-T for anti-FXa and anti-FIIa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amax for anti-FXa and anti-FIIa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants and Controls Enrolled in Biobank
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: recurrence of endometriomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient acceptance of the new liquid growth hormone formulation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Heart Age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ulcer Size Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoglobulin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity and Specificity Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Urine Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in treatment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRD conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Tumour load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Molecular relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants who completed the study during the 12 weeks' period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants who completed the study during the 24 weeks' period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of participants retained in the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline of WOMAC pain subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pro-inflammatory cytokines and complement activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: detectable immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of patients not requiring palliative surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Presence of microvascular invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Disease-specific Survival
Endpoint domain: Mortality/survival
Primary endpoint: adherence to dietary sodium targets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average daily interdialytic weight gain (IDWG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average pulse pressure from pre-dialysis blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Macular appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Positive for Delayed-type Hypersensitivity (DTH) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence to vitamin and mineral supplementation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Average Latency to Persistent Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Association between genetic lesion and outcome
Endpoint domain: Mortality/survival
Primary endpoint: Change in Connor-Davidson Resilience Scale (CDRISC)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Completion Rate of Adjuvant Chemotherapy and Radiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle protein synthesis rate (Fractional Synthetic Rate, FSR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite endpoint of mortality and clinical deterioration
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence rate of superficial surgical site infections
Endpoint domain: Adverse events/effects
Primary endpoint: Adenoma missing rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Characterization of breast tumors using MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Refusal of educational program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Action discrimination performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of repeat biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of repeat biopsies
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Morning Stiffness Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight growth velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cure rate against Trichuris trichiura
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hospitalization for recurrence of AF
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mortality within the first year of life
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline of Over Active Bladder questionnaire Short Form (OAB-q SF) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline of Patient Assessment of Treatment Satisfaction (TS-VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in EuroQol Group system (EQ-5D-5L) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Consistent contraception use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective Overall Quality of Vision
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Success rate of SVF extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in resting metabolic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of subjects with AFB sputum culture conversion to negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Hair Density Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Days of Primary Drug Used in the Prior 30 Days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total Dollar Value of Primary Drug Used in the Prior 30 Days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Glucose control - A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tumor specific survival time
Endpoint domain: Mortality/survival
Primary endpoint: Biochemical Pregnancy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change from baseline in Multiple Sclerosis Impact Scale 29 (MSIS-29)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Hospitalization for COVID-19
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Symptoms for COVID-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Return to Baseline Pain After Injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early and late neonatal measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean Percentage of Change in HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mortality rate among critical pneumonia patients
Endpoint domain: Mortality/survival
Primary endpoint: Attention measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Growth Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological status of retinoblastoma tumour suppressor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pelvic floor movement measured in x-y coordinates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: development of symptomatic aortic stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Wellbeing
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Abnormal Bladder Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Aggregate Sedative Exposure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Gastrointestinal Toxicities (Grade 3 and 4 Nausea and Vomiting)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in sputum load of Pseudomonas aeruginosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Quality of Life in Bronchiectasis-Respiratory Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of O3 Sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of cases exhibiting conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC0-τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Plasma Clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of successful reconstructions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Flare of IBD needing change in therapy or surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Microbiome change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index Z score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety post-FMT
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with a positive biopsy result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes of baseline cardiac rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of baseline oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperatory pain visual analogue scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes of motor block using Bromage scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of fitting of EEG pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of irritability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of times vomited
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nausea levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intensity of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean post void residual (PVR) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cormack-Lehane grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximal lipid oxidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Kidney rejection prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: High density lipoprotein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of grade 2 or worse Hand-Foot Skin Reaction (HFSR)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Maximum Concentration (Tmax) of Erenumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Erenumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Time Curve From 0 to 28 Days (AUC0-28day) of Erenumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left atrial pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fatigue complaints
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Depression and anxiety complaints
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sympathetic and parasympathetic nerve fiber balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with satisfying spontaneous voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Weekly rHuerythropoietin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity and specificity of the multiplex ELISA assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: StO2 in the First 10 Minutes of Life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Intradialytic Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dialysis Dysequilibrium
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of ER visits and hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Group Sessions Attended
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: sensitivity and specificity of CYFRA21-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IGF2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: IGF2 receptor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recirculation measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Reduction of Mean Pad Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days hospitalized within 90 days after transplant
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Episodes of acute cellular rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Time Within Target Blood Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in ADAS-COG+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: CIBIC+ Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual function quality (VF-14)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Antibiotic clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychological distress scale HADS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life scale SF-12
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AUC of Simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic stiffness and elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion Of Participants With A Clinical Outcome Of Cure, Improved, or Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion Of Participants With Positive Cultures For Gram Positive, Gram Negative, And Anaerobic Pathogens From The Infected Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion Of Participants With A Microbiologic Eradication Or Microbiologic Persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Positive-Pressure Ventilation Inflations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of PND
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of PND
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of throat-clearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 28-day Survival
Endpoint domain: Mortality/survival
Primary endpoint: Range of mandibular abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum displacement in frontal plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized displacement in frontal plane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes